论文部分内容阅读
目的综合评价有关阿达木单抗治疗类风湿性关节炎(RA)的药物经济学研究,探讨阿达木单抗联合传统DMARDs治疗RA的效果、成本及不良反应,比较不同种类TNF抑制剂的药物经济学价值。方法从Pubmed、MEDLINE等检索关于使用阿达木单抗治疗RA的药物经济学分析的英文文献,对研究质量进行评价,系统综述阿达木单抗治疗RA的国际药物经济学评估结果。结果纳入的7篇药物经济学评价文献显示,相较于传统的抗风湿药,阿达木单抗的治疗成本较高,但能显著提高RA患者的生命质量,改善病情,减少不良反应;阿达木单抗与MTX联用效果优于阿达木单抗单用。结论阿达木单抗成本较高,联合MTX等传统抗风湿药治疗能显著提高RA患者的生存收益,且不良反应发生率低,相对于其他TNF抑制剂在疗效和成本上具有一定优势,对传统DMARDs疗效不佳的RA患者具有经济性。
OBJECTIVE: To evaluate the pharmacological economics of adalimumab in the treatment of rheumatoid arthritis (RA) and to explore the effects, costs and adverse reactions of adalimumab in combination with traditional DMARDs in the treatment of rheumatoid arthritis. To compare the effects of different types of TNF inhibitors on drug economics Learning value. Methods The English literature on pharmacoeconomics analysis of rheumatoid arthritis with adalimumab was searched from Pubmed, MEDLINE and so on. The quality of the study was evaluated, and the international pharmacological evaluation of adalimumab in treating RA was systematically reviewed. Results The seven articles included in the review of pharmacoeconomic evaluation showed that adalimumab had a higher cost of treatment than traditional anti-rheumatic drugs, but significantly improved the quality of life, the improvement of the condition and the adverse reactions of AD patients. Adalimumab Monoclonal antibody combined with MTX is superior to adalimumab alone. Conclusion Adalimumab high cost, combined with conventional anti-rheumatic drugs MTX treatment can significantly improve the survival benefit of RA patients, and the incidence of adverse reactions is low, compared with other TNF inhibitors in the efficacy and cost has some advantages, the traditional RA patients with poorly-treated DMARDs are economically viable.